Características de los tratamientos biológicos en enfermedades reumáticas en Argentina: quinto informe del registro BIOBADASAR
Resumen
Introducción: el proyecto BIOBADASAR (Registro argentino de eventos adversos con tratamientos biológicos en reumatología) comenzó en agosto de 2010, para recabar información a largo plazo sobre los eventos adversos en tratamientos biológicos en pacientes con enfermedades reumáticas en la práctica clínica cotidiana en Argentina.Citas
I. Conti F, Ceccarelli F, Massaro L, Cipriano E, Di Franco M, Alessandri C, et al. Biological therapies in rheumatic diseases. Clin Ter [Internet]. 2013; 164(5):e413-28. Available from: http://www.ncbi. nlm.nih.gov/pubmed/24217844
II. Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD; BIOBADASER Group. Treatment of Rheumatoid Arthritis with Tumor Necrosis Factor Inhibitors May Predispose to Significant Increase in Tuberculosis Risk. Arthritis Rheum Aug 2003; 48(8):2122-2127.
III. Carmona L1, Descalzo MA, Perez-Pampin E, Ruiz-Montesinos D, Erra A, Cobo T, Gómez-Reino JJ; BIOBADASER and EMECAR Groups. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 2007; 66:880-885
IV. Dixon WG1, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register. Rates of Serious Infection, Including Site-Specific and Bacterial Intracellular Infection, in Rheumatoid Arthritis Patients Receiving Anti-Tumor Necrosis Factor Therapy. Arthritis Rheum Aug 2006; l54(8):2368-2376.
V. Harrison MJ et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor ± therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009; 68:209-215.
VI. Dixon WG, Watson KD, et al. Influence of Anti-Tumor Necrosis Factor Therapy on Cancer Incidence in Patients With rheumatoid Arthritis Who Have Had a Prior Malignancy. Results From the British Society for Rheumatology Biologics Register. Arthr Care &Research June 2010; 62(6):755-763.
VII. Askling J, Baecklund E, Granath F, et al Anti-tumor necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in Swedish Biologics Register. Ann Rheum Dis 2009; 68:648-653.
VIII. Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF ± agents. Jama, Feb 18, 2009: 301(7) 737-44.
IX. Kvien TK1, Heiberg, Lie E, Kaufmann C, Mikkelsen K, Nordvåg BY, Rødevand E. A Norwegian Register: Prescriptions of DMARDs and biological agents to patients with inflamatory rheumatic diseases. Clin Exp Rheumatol 2005; 23(Suppl 39):S188-S194.
X. Du Pan SM1, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A, Swiss Clinical Quality Management Physicians. Comparison of drug retention rates and causes of drug discontinuation betwen anti-tumor necrosis factor agents in rheumatoid Arthritis. Arthritis & Rheumatism may 15, 2009; 61(5):560-568.
XI. Greenberg JD1, Kremer JM, Curtis JR, et al. Tumour Necrosis Factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis. 2011 Apr; 70(4):576-82.
XII. T itton DC, Silveira IG, Louzada-Junior P, et al. Brazilian Biologic Register: Biobadabrasil implementation process and preliminary results. Rev Bras Reumatol 2011; 51(2):145-160.
XIII. D escalzo MÁ, Carmona L; Grupo de Estudio BIOBADASER. Biobadaser 2.0: análisis y tendencias en 2009. Reumatol Clin 2010; 6(5):240-243.
XIV. Gó mez-Reino JJ, Rodríguez-Lozano C, Campos-Fernández C, Montoro M, Descalzo MÁ, Carmona L. Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0. Ann Rheum Dis 2012; 71(3):382-5.
XV. Ramiro S, Gaujoux-Viala C, Nam JL, Smolen JS, Buch M, Gossec L, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis [Internet]. 2014; 73(3):529-35.
XVI. Ma X, Xu S. TNF inhibitor therapy for rheumatoid arthritis (Review). Biomed Reports [Internet]. 2013; 1(2):177-84.
XVII. H uynh D, Kavanaugh A. Psoriatic arthritis: current therapy and future approaches. Rheumatology [Internet]. 2015;54(1):20-8.
Derechos de autor 2016 Sociedad Argentina de Reumatología
Esta obra está bajo licencia internacional Creative Commons Reconocimiento-NoComercial-SinObrasDerivadas 4.0.
